Zileuton, a 5-Lypoxigenase Inhibitor, is Antiparasitic and Prevents Inflammation in the Chronic Stage of Heart Chagas Disease
2024

Zileuton: A Drug for Chagas Disease

Sample size: 28 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ricci Mayra Fernanda, Lourenço Estela Mariana Guimarães, Pereira Rafaela das Dores, Araújo Ronan Ricardo Sabino, Oliveira Fernando Bento Rodrigues, Barbosa da Silva Elany, de Oliveira Gabriel Stephani, Teixeira Mauro Martins, Rocha Nazareth de Novaes, Chambergo Felipe Santiago, Roman-Campos Danilo, Cruz Jader Santos, Ferreira Rafaela Salgado, Machado Fabiana Simão

Primary Institution: Universidade Federal de Minas Gerais

Hypothesis

Zileuton may have a protective effect in a murine model of chronic Chagas cardiomyopathy.

Conclusion

Zileuton shows promise as a treatment for Chagas disease by reducing parasitemia and improving cardiac function.

Supporting Evidence

  • Zileuton treatment reduced parasitemia in the early phase of infection.
  • Treatment improved cardiac function and reduced inflammation in the heart.
  • Zileuton increased SOCS2 expression, which is important for regulating inflammation.

Takeaway

Zileuton is a medicine that helps fight a disease called Chagas by making the heart work better and fighting the germs that cause it.

Methodology

The study used a murine model to test the effects of Zileuton on Trypanosoma cruzi infection and cardiac function.

Limitations

The study was conducted in a murine model, which may not fully replicate human responses.

Participant Demographics

Female C57BL/6 Wild-type mice aged 6–8 weeks were used.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1021/acsinfecdis.4c00623

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication